{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:35:16Z","timestamp":1793367316121,"version":"4.5.0"},"reference-count":183,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>The endocannabinoid system comprises cannabinoid receptors (CBRs) 1 &amp;amp; 2, endocannabinoids (eCBs) anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and the enzymes that regulate their production and degradation. ECS plays a significant role in both health and disease. It influences neuronal and glial communications, neurotransmitter regulations, neuroinflammation, and behavioral alterations. Neuropsychiatric symptoms (NPS) are commonly seen in neurodegenerative conditions like Alzheimer\u2019s disease (AD), apart from the core clinical diagnosis of dementia. NPS consists of various disturbing symptoms, including anxiety, agitation, apathy, hallucinations, delusions, sleeping problems, appetite problems, and depression. In AD, up to 97% exhibit one or more NPS. Emerging evidence from preclinical and clinical studies suggests that ECS is both a contributor to and a potential therapeutic target for managing NPS. This review explores ECS\u2019s role in NPS and its therapeutic implications.<\/jats:p>","DOI":"10.3389\/fpsyt.2025.1709266","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T11:31:13Z","timestamp":1768303873000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer\u2019s disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Jagadeesh S.","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alejandra Tangarife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Margarita","family":"Venegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Forero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Luc\u00eda","family":"Gonz\u00e1lez Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Escobar-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Rodr\u00edguez-Soacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ferreiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Mukunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.08.005","article-title":"Targeting the endocannabinoid system: future therapeutic strategies","volume":"22","author":"Aizpurua-Olaizola","year":"2017","journal-title":"Drug Discov Today"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.806417","article-title":"The dynamic role of microglia and the endocannabinoid system in neuroinflammation","volume":"12","author":"Young","year":"2021","journal-title":"Front Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.16.7656","article-title":"Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction","volume":"90","author":"Felder","year":"1993","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.161191698","article-title":"Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase","volume":"98","author":"Cravatt","year":"2001","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1017\/S1462399409000957","article-title":"Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation","volume":"11","author":"Cabral","year":"2009","journal-title":"Expert Rev Mol Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu Rev Psychol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-4105-9","article-title":"Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression","volume":"233","author":"Boorman","year":"2016","journal-title":"Psychopharmacol (Berl)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333819","article-title":"Neuropsychiatric symptoms in cognitive decline and Alzheimer's disease: biomarker discovery using plasma proteomics","volume":"96","author":"Rabl","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1263771","article-title":"Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment","volume":"17","author":"Pless","year":"2023","journal-title":"Front Neurosci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40268-019-0272-1","article-title":"Neuropsychiatric symptoms in dementia: considerations for pharmacotherapy in the USA","volume":"19","author":"Phan","year":"2019","journal-title":"Drugs R D"},{"key":"B12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7417\/CT.2023.5009","article-title":"Oral THC: CBD cannabis extract in main symptoms of Alzheimer disease: agitation and weight loss","author":"Palmieri","year":"2023","journal-title":"La Clinica Terapeutica"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.07.013","article-title":"CB1 cannabinoid receptor-mediated aggressive behavior","volume":"75","author":"Rodriguez-Arias","year":"2013","journal-title":"Neuropharmacology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150915","article-title":"Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study","volume":"51","author":"Shelef","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-131961","article-title":"Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the AbetaPPswe\/PS1DeltaE9 mouse model of Alzheimer's disease","volume":"42","author":"Maroof","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.neurobiolaging.2012.06.011","article-title":"Activation of the CB2 receptor system reverses amyloid-induced memory deficiency","volume":"34","author":"Wu","year":"2013","journal-title":"Neurobiol Aging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-9-8","article-title":"Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice","volume":"9","author":"Martin-Moreno","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2013.06.004","article-title":"Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier","volume":"56","author":"Bachmeier","year":"2013","journal-title":"Mol Cell Neurosci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2006.06.012","article-title":"CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons","volume":"404","author":"Esposito","year":"2006","journal-title":"Neurosci Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.08.007","article-title":"Genetic deletion of CB(1) cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model","volume":"157","author":"Aso","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms24010026","article-title":"Hippocampal deletion of CB1 receptor impairs social memory and leads to age-related changes in the hippocampus of adult mice","author":"Palmisano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr046","article-title":"Molecular reorganization of endocannabinoid signalling in Alzheimer's disease","volume":"134","author":"Mulder","year":"2011","journal-title":"Brain"},{"key":"B23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrn3876","article-title":"Endocannabinoid signalling and the deteriorating brain","volume":"16","author":"Di Marzo","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2010.04.015","article-title":"Prevalence of neuropsychiatric syndromes in Alzheimer's disease (AD)","volume":"52","author":"Youn","year":"2011","journal-title":"Arch Gerontol Geriatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000074080","article-title":"Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction","volume":"17","author":"Senanarong","year":"2004","journal-title":"Dement Geriatr Cognit Disord"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.644317","article-title":"Agitation and dementia: prevention and treatment strategies in acute and chronic conditions","volume":"12","author":"Carrarini","year":"2021","journal-title":"Front Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/S1041610214001963","article-title":"Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition","volume":"27","author":"Cummings","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1412901","article-title":"Neurobiological alteration in agitation in Alzheimer's disease and possible interventions","volume":"15","author":"Rao","year":"2024","journal-title":"Front Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jdad2020015","article-title":"Dysregulated neurotransmitters and receptor dysfunction and their roles in agitation associated with alzheimer\u2019s disease","volume":"2","author":"Rao","year":"2025","journal-title":"J Dement Alzheimer\u2019s Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12915","article-title":"Involvement of inflammation in the medial temporal region in the development of agitation in Alzheimer's disease: an in vivo positron emission tomography study","volume":"23","author":"Yasuno","year":"2023","journal-title":"Psychogeriatrics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.974905","article-title":"The NLRP3 inflammasome is involved in resident intruder paradigm-induced aggressive behaviors in mice","volume":"14","author":"Yu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140492","article-title":"Type-1 cannabinoid receptor activity during Alzheimer's disease progression","volume":"42","author":"Manuel","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"B33","first-page":"5","article-title":"The pathophysiology of agitation","author":"Lindenmayer","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ana.72","article-title":"Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease","volume":"49","author":"Tekin","year":"2001","journal-title":"Ann Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200600","article-title":"Pathological correlations of neuropsychiatric symptoms in institutionalized people with dementia","volume":"78","author":"Esteban de Antonio","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.6.861","article-title":"Left frontotemporal hypoperfusion is associated with aggression in patients with dementia","volume":"57","author":"Hirono","year":"2000","journal-title":"Arch Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2017.01.017","article-title":"(18)F-fluorodeoxyglucose positron emission tomography cortical metabolic activity associated with distinct agitation behaviors in alzheimer disease","volume":"25","author":"Weissberger","year":"2017","journal-title":"Am J Geriatr Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2174\/1567205019666211220130505","article-title":"Correlation of neuropsychiatric symptoms in dementia with brain perfusion: A 99mTc-SPECT-HMPAO study with brodmann areas analysis","volume":"18","author":"Valotassiou","year":"2021","journal-title":"Curr Alzheimer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12974-020-01820-6","article-title":"The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study","volume":"17","author":"Ismail","year":"2020","journal-title":"J Neuroinflamm"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2008.08.006","article-title":"Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface","volume":"23","author":"Miller","year":"2009","journal-title":"Brain Behav Immun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"122457","DOI":"10.1016\/j.lfs.2024.122457","article-title":"Cognitive impairment in Alzheimer's disease FAD(4T) mouse model: Synaptic loss facilitated by activated microglia via C1qA","volume":"340","author":"Zhang","year":"2024","journal-title":"Life Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(94)90511-8","article-title":"Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains","volume":"63","author":"Westlake","year":"1994","journal-title":"Neuroscience"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.415367","article-title":"delta9-tetrahydrocannabinol: antiaggressive effects in mice, rats, and squirrel monkeys","volume":"199","author":"Miczek","year":"1978","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.145425","article-title":"Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when G(i) protein-receptor coupling is restricted: role of dopamine D2 receptors","volume":"328","author":"Gonzalez","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.12690","article-title":"Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortex","volume":"40","author":"Cathel","year":"2014","journal-title":"Eur J Neurosci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(76)90038-2","article-title":"Effects of delta9-tetrahydrocannabinol on neurotransmitter accumulation and release mechanisms in rat forebrain synaptosomes","volume":"19","author":"Johnson","year":"1976","journal-title":"Life Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1099-1166","article-title":"Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease","volume":"12","author":"Volicer","year":"1997","journal-title":"Int J Geriatr Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0343-1","article-title":"Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia","volume":"185","author":"Walther","year":"2006","journal-title":"Psychopharmacol (Berl)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2012.11.022","article-title":"Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms","volume":"22","author":"Woodward","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized placebo-controlled trial of nabilone for agitation in alzheimer's disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"101998","DOI":"10.1016\/j.arr.2023.101998","article-title":"Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy","volume":"90","author":"Fonseca","year":"2023","journal-title":"Ageing Res Rev"},{"key":"B52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms23105526","article-title":"Modulation of endocannabinoid system components in depression: pre-clinical and clinical evidence","author":"Bright","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41398-020-0787-9","article-title":"Neurovegetative symptom subtypes in young people with major depressive disorder and their structural brain correlates","volume":"10","author":"Toenders","year":"2020","journal-title":"Transl Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1966","DOI":"10.1002\/mpr.1966","article-title":"The Major Depression Inventory for diagnosing according to DSM-5 and ICD-11: Psychometric properties and validity in a Swedish general population","volume":"32","author":"Lundin","year":"2023","journal-title":"Int J Methods Psychiatr Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.5.530","article-title":"Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis","volume":"63","author":"Ownby","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.8.1290","article-title":"Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study","volume":"61","author":"Modrego","year":"2004","journal-title":"Arch Neurol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1212\/WNL.0b013e3181e62138","article-title":"Depressive symptoms and risk of dementia: the Framingham Heart Study","volume":"75","author":"Saczynski","year":"2010","journal-title":"Neurology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-161247","article-title":"Efficacy of antidepressants for depression in alzheimer's disease: systematic review and meta-analysis","volume":"58","author":"Orgeta","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.10068","article-title":"Depression in Alzheimer's disease: the effect of serotonin receptor gene variation","author":"Holmes","year":"2003","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejphar.2009.10.022","article-title":"Depression and Alzheimer's disease: neurobiological links and common pharmacological targets","volume":"626","author":"Caraci","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.07.001","article-title":"Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms","volume":"3","author":"Lanctot","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e31816029ec","article-title":"Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression","volume":"16","author":"Rapp","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.07.008","article-title":"Trajectories of depressive symptoms and their relationship to the progression of dementia","volume":"222","author":"Barca","year":"2017","journal-title":"J Affect Disord"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e12584","DOI":"10.1002\/dad2.12584","article-title":"Risk of depression in persons with Alzheimer's disease: A national cohort study","volume":"16","author":"Crump","year":"2024","journal-title":"Alzheimers Dement (Amst)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms22179472","article-title":"The endocannabinoid system: A potential target for the treatment of various diseases","author":"Lowe","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms23094764","article-title":"Molecular alterations of the endocannabinoid system in psychiatric disorders","author":"Navarro","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2011.82","article-title":"Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers","volume":"17","author":"Hirvonen","year":"2012","journal-title":"Mol Psychiatry"},{"key":"B68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms22041867","article-title":"Discovering the lost reward: critical locations for endocannabinoid modulation of the cortico-striatal loop that are implicated in major depression","author":"Goldstein","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000453","article-title":"Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers","volume":"13","author":"Horder","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms23020975","article-title":"New insights and potential therapeutic targeting of CB2 cannabinoid receptors in CNS disorders","author":"Kibret","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00315","article-title":"Endocannabinoid system components as potential biomarkers in psychiatry","volume":"11","author":"Navarrete","year":"2020","journal-title":"Front Psychiatry"},{"key":"B72","doi-asserted-by":"publisher","first-page":"120221","DOI":"10.1016\/j.jep.2025.120221","article-title":"Saikosaponin C ameliorates tau-related pathology by modulating oxidative stress and MAPK axis in Alzheimer's disease","volume":"352","author":"Chen","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1130989","article-title":"Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories","volume":"14","author":"Hassamal","year":"2023","journal-title":"Front Psychiatry"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0385-7","article-title":"Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH\/MAGL inhibitors","volume":"41","author":"Ren","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.01.073","article-title":"Activation of murine microglial N9 cells is attenuated through cannabinoid receptor CB2 signaling","volume":"458","author":"Ma","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B76","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms22010019","article-title":"CB2 receptor in microglia: the guardian of self-control","author":"Komorowska-Muller","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"101782","DOI":"10.1016\/j.arr.2022.101782","article-title":"Prevalence of sleep disturbances in people with dementia living in the community: A systematic review and meta-analysis","volume":"83","author":"Koren","year":"2023","journal-title":"Ageing Res Rev"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8739","article-title":"Glymphatic failure as a final common pathway to dementia","volume":"370","author":"Nedergaard","year":"2020","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00330","article-title":"Sleep disorders associated with alzheimer's disease: A perspective","volume":"12","author":"Brzecka","year":"2018","journal-title":"Front Neurosci"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1053942","article-title":"Sleep deficiency promotes Alzheimer's disease development and progression","volume":"13","author":"Lv","year":"2022","journal-title":"Front Neurol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/JAD-215324","article-title":"Burden of insomnia and sleep disturbances and the impact of sleep treatments in patients with probable or possible alzheimer's disease: A structured literature review","volume":"86","author":"Benca","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"B83","doi-asserted-by":"publisher","first-page":"111899","DOI":"10.1016\/j.mad.2023.111899","article-title":"Sleep disorders and Alzheimer's disease pathophysiology: The role of the Glymphatic System","volume":"217","author":"Astara","year":"2024","journal-title":"A scoping review.Mech Ageing Dev"},{"key":"B84","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijerph19148457","article-title":"Sleep quality and aging: A systematic review on healthy older people, mild cognitive impairment and alzheimer's disease","author":"Casagrande","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B85","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41398-022-01897-y","article-title":"Sleep in Alzheimer's disease: a systematic review and meta-analysis of polysomnographic findings","volume":"12","author":"Zhang","year":"2022","journal-title":"Transl Psychiatry"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2025.1428733","article-title":"The role of sleep in Alzheimer's disease: a mini review","volume":"19","author":"Pathmanathan","year":"2025","journal-title":"Front Neurosci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.4103\/NRR.NRR-D-24-00351","article-title":"Sleep as a window to understand and regulate Alzheimer's disease: emerging roles of thalamic reticular nucleus","volume":"20","author":"Sun","year":"2025","journal-title":"Neural Regener Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2022.07.012","article-title":"Correlations between sleep disturbance and brain structures associated with neurodegeneration in the National Alzheimer's Coordinating Center Uniform Data Set","volume":"106","author":"Burke","year":"2022","journal-title":"J Clin Neurosci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ijms25063160","article-title":"Sleep, glial function, and the endocannabinoid system: implications for neuroinflammation and sleep disorders","author":"Camberos-Barraza","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2005.12.028","article-title":"Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat","volume":"79","author":"Murillo-Rodriguez","year":"2006","journal-title":"Life Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-003-3453-5","article-title":"Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain","volume":"61","author":"Valenti","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.00125","article-title":"Cannabinoids, endocannabinoids and sleep","volume":"13","author":"Kesner","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2007.06.011","article-title":"Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins","volume":"54","author":"Matias","year":"2008","journal-title":"Neuropharmacology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(98)00969-X","article-title":"Anandamide modulates sleep and memory in rats","volume":"812","author":"Murillo-Rodriguez","year":"1998","journal-title":"Brain Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200107200-00018","article-title":"Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor","volume":"12","author":"Murillo-Rodriguez","year":"2001","journal-title":"Neuroreport"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2010.02.044","article-title":"Intrahippocampal administration of anandamide increases REM sleep","volume":"473","author":"Rueda-Orozco","year":"2010","journal-title":"Neurosci Lett"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12109","article-title":"Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial","volume":"16","author":"Rios-Romenets","year":"2020","journal-title":"Alzheimers Dement"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12643","article-title":"Systematic review\/meta-analysis on the role of CB1R regulation in sleep-wake cycle in rats","volume":"17","author":"Xue","year":"2024","journal-title":"J Evid Based Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbb.2013.04.006","article-title":"2-AG into the lateral hypothalamus increases REM sleep and cFos expression in melanin concentrating hormone neurons in rats","volume":"108","author":"Perez-Morales","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.5546","article-title":"Sleep restriction enhances the daily rhythm of circulating levels of endocannabinoid 2-arachidonoylglycerol","volume":"39","author":"Hanlon","year":"2016","journal-title":"Sleep"},{"key":"B101","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/bs.vh.2024.02.003","article-title":"Sleep loss impairs blood-brain barrier function: Cellular and molecular mechanisms","volume":"126","author":"Avilez-Avilez","year":"2024","journal-title":"Vitam Horm"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0619-21.2021","article-title":"The glymphatic system: A novel component of fundamental neurobiology","volume":"41","author":"Hablitz","year":"2021","journal-title":"J Neurosci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx148","article-title":"Slow wave sleep disruption increases cerebrospinal fluid amyloid-beta levels","volume":"140","author":"Ju","year":"2017","journal-title":"Brain"},{"key":"B104","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ph17030319","article-title":"Evaluating fatty acid amide hydrolase as a suitable target for sleep promotion in a transgenic tauP301S mouse model of neurodegeneration","author":"Martin","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2024.1401698","article-title":"Astrocyte regulation of extracellular space parameters across the sleep-wake cycle","volume":"18","author":"Sriram","year":"2024","journal-title":"Front Cell Neurosci"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s12017-014-8314-x","article-title":"Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier","volume":"16","author":"Vendel","year":"2014","journal-title":"Neuromolecular Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/cells13020150","article-title":"Involvement of astrocytes in the formation, maintenance, and function of the blood-brain barrier","volume":"13","author":"Schiera","year":"2024","journal-title":"Cells"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.951889","article-title":"Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial","volume":"9","author":"Hermush","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.04.24311473","article-title":"Prevalence, risk factors, and impact of anxiety in early Alzheimer disease: a retrospective study of an autopsy-confirmed cohort","author":"Patel","year":"2024","journal-title":"medRxiv"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)13195-9","article-title":"Pharmacological characterization of cannabinoids in the elevated plus maze","volume":"253","author":"Onaivi","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2003.12.019","article-title":"Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test","volume":"77","author":"Genn","year":"2004","journal-title":"Pharmacol Biochem Behav"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704479","article-title":"Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine","volume":"135","author":"Valjent","year":"2002","journal-title":"Br J Pharmacol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1144-9","article-title":"Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol","volume":"163","author":"Berrendero","year":"2002","journal-title":"Psychopharmacol (Berl)"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2005.01.029","article-title":"Endocannabinoid system and stress and anxiety responses","volume":"81","author":"Viveros","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2002.02192.x","article-title":"The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety","volume":"16","author":"Haller","year":"2002","journal-title":"Eur J Neurosci"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1159\/000541364","article-title":"Treatment of neuropsychiatric symptoms in alzheimer's disease with a cannabis-based magistral formulation: an open-label prospective cohort study","volume":"7","author":"Navarro","year":"2024","journal-title":"Med Cannabis Cannabinoids"},{"key":"B117","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/brain\/awaa413","article-title":"Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms","volume":"144","author":"Naasan","year":"2021","journal-title":"Brain"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1777774","article-title":"Behavioral or neuropsychiatric symptoms of Alzheimer's disease: from psychopathology to pharmacological management","volume":"81","author":"Teixeira","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150944","article-title":"Delusions in patients with alzheimer's disease: A multidimensional approach","volume":"51","author":"D'Onofrio","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01133-9","article-title":"Emerging pharmacological approaches for psychosis and agitation in alzheimer's disease","volume":"39","author":"Imbimbo","year":"2025","journal-title":"CNS Drugs"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.808724","article-title":"Delusion and delirium in neurodegenerative disorders: an overlooked relationship","volume":"12","author":"Urso","year":"2021","journal-title":"Front Psychiatry"},{"key":"B122","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13024-021-00456-1","article-title":"Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns","volume":"16","author":"Chen","year":"2021","journal-title":"Mol Neurodegener"},{"key":"B123","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/gps.5692","article-title":"Examining the presence and nature of delusions in Alzheimer's disease and frontotemporal dementia syndromes","author":"Kumfor","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4265","article-title":"Cognitive phenotype of psychotic symptoms in Alzheimer's disease: evidence for impaired visuoperceptual function in the misidentification subtype","volume":"30","author":"Reeves","year":"2015","journal-title":"Int J Geriatr Psychiatry"},{"key":"B125","doi-asserted-by":"publisher","first-page":"e031947","DOI":"10.1136\/bmjopen-2019-031947","article-title":"Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study","volume":"9","author":"Goukasian","year":"2019","journal-title":"BMJ Open"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1427","article-title":"In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis","volume":"76","author":"Borgan","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J Neurosci"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB2 receptor and its role as a regulator of inflammation","volume":"73","author":"Flamand","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B129","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.ajp.2015.15111377","article-title":"Microglial activation and the onset of psychosis","volume":"173","author":"Cannon","year":"2016","journal-title":"Am J Psychiatry"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.2174\/138161212802884681","article-title":"A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation","volume":"18","author":"Zuardi","year":"2012","journal-title":"Curr Pharm Des"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2001.49282.x","article-title":"Apathy in alzheimer's disease","volume":"49","author":"Landes","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"B132","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cobeha.2017.12.007","article-title":"Apathy in alzheimer's disease","volume":"22","author":"Nobis","year":"2018","journal-title":"Curr Opin Behav Sci"},{"key":"B133","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1017\/S1041610213001725","article-title":"A review of neuroimaging findings of apathy in Alzheimer's disease","volume":"26","author":"Theleritis","year":"2014","journal-title":"Int Psychogeriatr"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1159\/000090674","article-title":"Neuropathologic correlates of apathy in Alzheimer's disease","volume":"21","author":"Marshall","year":"2006","journal-title":"Dement Geriatr Cognit Disord"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fncir.2022.939235","article-title":"The role of dopamine and endocannabinoid systems in prefrontal cortex development: Adolescence as a critical period","volume":"16","author":"Peters","year":"2022","journal-title":"Front Neural Circuits"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04333-y","article-title":"An expanded narrative review of neurotransmitters on alzheimer's disease: the role of therapeutic interventions on neurotransmission","volume":"62","author":"Akyuz","year":"2025","journal-title":"Mol Neurobiol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-024-01359-x","article-title":"Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms","volume":"47","author":"Saggu","year":"2025","journal-title":"Geroscience"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12088","article-title":"GABAergic dysfunction in excitatory and inhibitory (E\/I) imbalance drives the pathogenesis of Alzheimer's disease","volume":"16","author":"Bi","year":"2020","journal-title":"Alzheimers Dement"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2023.1137957","article-title":"Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation","volume":"17","author":"Kibret","year":"2023","journal-title":"Front Behav Neurosci"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00252","article-title":"Is dopamine involved in Alzheimer's disease","volume":"6","author":"Martorana","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-130050","article-title":"Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy","volume":"35","author":"Casarejos","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.016428","article-title":"Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity","volume":"69","author":"Kim","year":"2006","journal-title":"Mol Pharmacol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14098","article-title":"Endocannabinoid system in neurodegenerative disorders","volume":"142","author":"Basavarajappa","year":"2017","journal-title":"J Neurochem"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200506000-00004","article-title":"A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease","volume":"13","author":"Craig","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000001134","article-title":"A critical review of behavioral and emotional disinhibition","volume":"208","author":"Huey","year":"2020","journal-title":"J Nerv Ment Dis"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.cortex.2020.08.001","article-title":"Cognitive and behavioural inhibition deficits in neurodegenerative dementias","volume":"131","author":"Migliaccio","year":"2020","journal-title":"Cortex"},{"key":"B147","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000086474","article-title":"Acquired sociopathy and frontotemporal dementia","volume":"20","author":"Mendez","year":"2005","journal-title":"Dement Geriatr Cognit Disord"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac133","article-title":"A transdiagnostic review of neuroimaging studies of apathy and disinhibition in dementia","volume":"145","author":"Jenkins","year":"2022","journal-title":"Brain"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610222000151","article-title":"Pharmacological and nonpharmacological approaches to reduce disinhibited behaviors in dementia: a systematic review","volume":"34","author":"Burley","year":"2022","journal-title":"Int Psychogeriatr"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00596","article-title":"The use of risperidone in behavioral and psychological symptoms of dementia: A review of pharmacology, clinical evidence, regulatory approvals, and off-label use","volume":"11","author":"Yunusa","year":"2020","journal-title":"Front Pharmacol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.5152\/npa.","article-title":"Management of behavioral and psychological symptoms of dementia","volume":"51","author":"Sahin Cankurtaran","year":"2014","journal-title":"Noro Psikiyatr Ars"},{"key":"B152","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10072-011-0618-0","article-title":"Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study","volume":"33","author":"Clerici","year":"2012","journal-title":"Neurol Sci"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12140","article-title":"Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies","volume":"16","author":"Manabe","year":"2016","journal-title":"Psychogeriatrics"},{"key":"B154","doi-asserted-by":"publisher","first-page":"d4065","DOI":"10.1136\/bmj.d4065","article-title":"Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial","volume":"343","author":"Husebo","year":"2011","journal-title":"BMJ"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2011.00063","article-title":"Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects","volume":"5","author":"Marco","year":"2011","journal-title":"Front Behav Neurosci"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2009.07.014","article-title":"Bidirectional regulation of novelty-induced behavioral inhibition by the endocannabinoid system","volume":"57","author":"Lafenetre","year":"2009","journal-title":"Neuropharmacology"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12380","article-title":"Cachexia and advanced dementia","volume":"10","author":"Minaglia","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B158","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0197-4580(88)80004-6","article-title":"Anorexia in the elderly","volume":"9","author":"Morley","year":"1988","journal-title":"Neurobiol Aging"},{"key":"B159","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.3390\/ijms25105378","article-title":"Cannabinoid and orexigenic systems interplay as a new focus of research in alzheimer\u2019s disease","volume":"25","author":"Rebassa","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.10.1556","article-title":"Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease","volume":"62","author":"Kivipelto","year":"2005","journal-title":"Arch Neurol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ageing\/afv151","article-title":"The risk of overweight\/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies","volume":"45","author":"Pedditizi","year":"2016","journal-title":"Age Ageing"},{"key":"B162","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/ph18060890","article-title":"Recent preclinical evidence on phytocannabinoids in neurodegenerative disorders: A focus on parkinson\u2019s and alzheimer\u2019s disease","volume":"18","author":"Blebea","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2018.08.002","article-title":"CB1 receptors in the paraventricular nucleus of the hypothalamus modulate the release of 5-HT and GABA to stimulate food intake in rats","volume":"28","author":"Cruz-Mart\u00ednez","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2008.09.007","article-title":"Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia nervosa","volume":"43","author":"St\u00f8ving","year":"2009","journal-title":"J Psychiatr Res"},{"key":"B165","doi-asserted-by":"publisher","first-page":"432607","DOI":"10.1155\/2011\/432607","article-title":"Rimonabant: from RIO to ban","volume":"2011","author":"Sam","year":"2011","journal-title":"J Obes"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1053680","article-title":"Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer\u2019s disease: A systematic review and meta-analysis of animal studies","volume":"14","author":"Kamaruzzaman","year":"2023","journal-title":"Front Pharmacol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.3390\/ijms26146570","article-title":"Anti-inflammatory effects of cannabinoids in therapy of neurodegenerative disorders and inflammatory diseases of the CNS","volume":"26","author":"Tomaszewska-Zaremba","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1998.tb04537.x","article-title":"The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis","volume":"46","author":"White","year":"1998","journal-title":"J Am Geriatrics Soc"},{"key":"B169","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/brain\/aww349","article-title":"An early and late peak in microglial activation in Alzheimer's disease trajectory","volume":"140","author":"Fan","year":"2017","journal-title":"Brain"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.10.010","article-title":"Plaque-associated local toxicity increases over the clinical course of alzheimer disease","volume":"186","author":"Serrano-Pozo","year":"2016","journal-title":"Am J Pathol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cells11091391","article-title":"Cannabinoids alleviate the LPS-induced cytokine storm via attenuating NLRP3 inflammasome signaling and TYK2-mediated STAT3 signaling pathways in vitro","author":"Suryavanshi","year":"2022","journal-title":"Cells"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04961.x","article-title":"CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A\/C receptors","volume":"103","author":"Mato","year":"2007","journal-title":"J Neurochem"},{"key":"B173","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/gps.5814","article-title":"Sleep disturbances in Lewy body dementia: A systematic review","author":"Elder","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2008.04.008","article-title":"The role of the CB1 receptor in the regulation of sleep","volume":"32","author":"Murillo-Rodriguez","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B175","doi-asserted-by":"publisher","first-page":"e89432","DOI":"10.1371\/journal.pone.0089432","article-title":"Multiple sleep alterations in mice lacking cannabinoid type 1 receptors","volume":"9","author":"Silvani","year":"2014","journal-title":"PloS One"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/nn879","article-title":"Endocannabinoids facilitate the induction of LTP in the hippocampus","volume":"5","author":"Carlson","year":"2002","journal-title":"Nat Neurosci"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18103\/mra.v12i4.5380","article-title":"A study on CYP2C9 polymorphism in Puerto Rican Alzheimer's Patients and its role in the Pharmacokinetics of \u0394-9-tetrahydrocanna-binol","volume":"12","author":"Jagadeesh","year":"2024","journal-title":"Med Reseach Arch"},{"key":"B178","doi-asserted-by":"publisher","first-page":"e70549","DOI":"10.1002\/alz.70549","article-title":"Leveraging multiomic approaches to elucidate mechanisms of heterogeneity in Alzheimer's disease: Neuropsychiatric symptoms, co-pathologies, and sex differences","volume":"21","author":"Shwab","year":"2025","journal-title":"Alzheimers Dement"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01152-8","article-title":"Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease","volume":"26","author":"DeMichele-Sweet","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2020.01.001","article-title":"Psychosis-associated DNA methylomic variation in Alzheimer's disease cortex","volume":"89","author":"Pishva","year":"2020","journal-title":"Neurobiol Aging"},{"key":"B181","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41398-024-02878-z","article-title":"Unique transcriptional signatures correlate with behavioral and psychological symptom domains in Alzheimer's disease","volume":"14","author":"Fisher","year":"2024","journal-title":"Transl Psychiatry"},{"key":"B182","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13195-022-00991-z","article-title":"Sex differences in neuropsychiatric symptoms in Alzheimer's disease dementia: a meta-analysis","volume":"14","author":"Eikelboom","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"B183","doi-asserted-by":"publisher","first-page":"e70622","DOI":"10.1002\/alz.70622","article-title":"Neuropsychiatric symptom subtypes and dementia-associated neuropathologic change","volume":"21","author":"Cholerton","year":"2025","journal-title":"Alzheimers Dement"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1709266\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T11:31:15Z","timestamp":1768303875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1709266\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":183,"alternative-id":["10.3389\/fpsyt.2025.1709266"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1709266","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1709266"}}